Metastatic prostate cancer has traditionally been treated with systemic therapy alone, but the issue of oligometastatic disease raises the question of whether local therapy — radical prostatectomy or prostate radiotherapy — should be performed. A number of phase III trials should improve our understanding of metastatic disease and lead to better care of our patients.
This is a preview of subscription content, log in via an institution to check access.
References
Tosoian, J. J. et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat. Rev. Urol. 14, 15–25 (2017).
Dall’Era, M. A. et al. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer. Cancer 124, 1921–1928 (2018).
Lee, S. U. & Cho, K. H. Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy &rogen deprivation therapy and their combination. Radiat. Oncol. J. 35, 189–197 (2017).
Weichselbaum, R. R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8, 378–382 (2011).
deSouza, N. M. et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur. J. Cancer. 91, 153–163 (2018).
Sooriakumaran, P. et al. Multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur. Urol. 69, 788–794 (2016).
Heidenreich, A., Pfister, D. & Porres, D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J. Urol. 193, 832–838 (2015).
Stewart, S. B. et al. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J. Urol. 187, 103–108 (2012).
Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446–453 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares research support from and has acted as an adviser or speaker for Astellas, Bayer, Dendreon, Janssen, Ferring, Pfizer, and Sanofi.
Rights and permissions
About this article
Cite this article
Moul, J.W. Yes or no to local therapy for oligometastatic prostate cancer?. Nat Rev Urol 15, 399–400 (2018). https://doi.org/10.1038/s41585-018-0028-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0028-7
- Springer Nature Limited